Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

作者: Jon Reynolds

DOI: 10.2147/DMSOTT.S4637

关键词:

摘要: Janumet(TM,) a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment patients with type 2 diabetes, that are inadequately controlled, either sitagliptin or metformin alone together in free-dose form. Sitagliptin, an inhibitor the enzyme DDP-4, assists diabetes mellitus to achieve glycemic control. It been shown be safe effective at 100 mg daily doses. The effect giving is thought have complimentary possibly additive on

参考文章(42)
R. Scott, M. Wu, M. Sanchez, P. Stein, Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice. ,vol. 61, pp. 171- 180 ,(2006) , 10.1111/J.1742-1241.2006.01246.X
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch, Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus Cochrane Database of Systematic Reviews. ,(2008) , 10.1002/14651858.CD006739.PUB2
Nicolas F. Wiernsperger, Clifford J. Bailey, The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. ,vol. 58, pp. 31- 39 ,(1999) , 10.2165/00003495-199958001-00009
R. Brazg, L. Xu, C. Dalla Man, C. Cobelli, K. Thomas, P. P. Stein, Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes Diabetes, Obesity and Metabolism. ,vol. 9, pp. 186- 193 ,(2007) , 10.1111/J.1463-1326.2006.00691.X
Garry G Graham, Jeroen Punt, Manit Arora, Richard O Day, Matthew P Doogue, Janna K Duong, Timothy J Furlong, Jerry R Greenfield, Louise C Greenup, Carl M Kirkpatrick, John E Ray, Peter Timmins, Kenneth M Williams, Clinical pharmacokinetics of metformin. Clinical Pharmacokinectics. ,vol. 30, pp. 359- 371 ,(1996) , 10.2165/00003088-199630050-00003
Goutam C. Mistry, Arthur J. Bergman, Wen-Lin Luo, Caroline Cilissen, Wouter Haazen, Michael J. Davies, Keith M. Gottesdiener, John A. Wagner, Gary A. Herman, Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. The Journal of Clinical Pharmacology. ,vol. 47, pp. 159- 164 ,(2007) , 10.1177/0091270006297007
Renee E. Amori, Joseph Lau, Anastassios G. Pittas, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. ,vol. 298, pp. 194- 206 ,(2007) , 10.1001/JAMA.298.2.194
Rajesh Krishna, Arthur Bergman, Patrick Larson, Josee Cote, Kenneth Lasseter, Stacey Dilzer, Amy Wang, Wei Zeng, Li Chen, John Wagner, Gary Herman, Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology. ,vol. 47, pp. 165- 174 ,(2007) , 10.1177/0091270006296523